Literature DB >> 6635446

Rifampin in chlamydial infections.

J Schachter.   

Abstract

On a weight basis, rifampin is the antibiotic most active against Chlamydia trachomatis. Because of concerns about the ease with which resistance to rifampin emerges in vitro, few clinical trials of rifampin for the treatment of human chlamydial infections have been done. In those few studies, however, rifampin has been found to be as effective as tetracyclines for the treatment of C. trachomatis infection of the male urethra or for the topical treatment of trachoma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6635446     DOI: 10.1093/clinids/5.supplement_3.s562

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  12 in total

1.  Infection by airborne Chlamydia trachomatis in a dentist cured with rifampicin after failures with tetracycline and doxycycline.

Authors:  M Midulla; D Sollecito; F Feleppa; A M Assensio; S Ilari
Journal:  Br Med J (Clin Res Ed)       Date:  1987-03-21

2.  Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil.

Authors:  Robert J Suchland; Agnès Bourillon; Erick Denamur; Walter E Stamm; David M Rothstein
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.

Authors:  Andrei Kutlin; Stephan Kohlhoff; Patricia Roblin; Margaret R Hammerschlag; Paul Riska
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis.

Authors:  Minsheng Xia; Robert J Suchland; Joli A Carswell; John Van Duzer; Debra K Buxton; Kara Brown; David M Rothstein; Walter E Stamm
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  Mass treatment with single-dose azithromycin for trachoma.

Authors:  Anthony W Solomon; Martin J Holland; Neal D E Alexander; Patrick A Massae; Aura Aguirre; Angels Natividad-Sancho; Sandra Molina; Salesia Safari; John F Shao; Paul Courtright; Rosanna W Peeling; Sheila K West; Robin L Bailey; Allen Foster; David C W Mabey
Journal:  N Engl J Med       Date:  2004-11-04       Impact factor: 91.245

6.  Growth cycle-dependent pharmacodynamics of antichlamydial drugs.

Authors:  Katrin Siewert; Jan Rupp; Matthias Klinger; Werner Solbach; Jens Gieffers
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

Review 7.  Use of rifampin in nonstaphylococcal, nonmycobacterial disease.

Authors:  A B Morris; R B Brown; M Sands
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

8.  Isolation and initial characterization of a series of Chlamydia trachomatis isolates selected for hydroxyurea resistance by a stepwise procedure.

Authors:  G Tipples; G McClarty
Journal:  J Bacteriol       Date:  1991-08       Impact factor: 3.490

9.  In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries.

Authors:  J Gieffers; W Solbach; M Maass
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

Review 10.  Application of molecular tools in the control of blinding trachoma.

Authors:  David Mabey; Anthony W Solomon
Journal:  Am J Trop Med Hyg       Date:  2003-11       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.